lidocaine has been researched along with Reperfusion Injury in 46 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
Excerpt | Relevance | Reference |
---|---|---|
"The primary aim of this study was to compare the effects of a small-dose infusion of 2 antioxidant agents, ketamine and lidocaine, on ischemia-reperfusion injury (IRI) in patients undergoing elective lower limb surgery." | 9.30 | The effects of ketamine and lidocaine on free radical production after tourniquet-induced ischemia-reperfusion injury in adults. ( Deyişli, C; Kıyıcı, A; Ökesli, S; Peker, K, 2019) |
" This study aimed to investigate whether lidocaine relieves SCIRI via modulating myocardial infarction-associated transcript (MIAT)-mediated Notch1 downregulation." | 8.12 | Lidocaine relieves spinal cord ischemia-reperfusion injury via long non-coding RNA MIAT-mediated Notch1 downregulation. ( Hou, J; Li, H; Ma, J; Xue, C, 2022) |
"To evaluate the effects of an intraperitoneal solution of methylene blue (MB), lidocaine and pentoxyphylline (PTX) on intestinal ischemic and reperfusion injury." | 7.83 | Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats. ( Cerri, S; Farca, AM; Gandini, M; Giusto, G; Iussich, S; Pregel, P; Tursi, M; Vercelli, C, 2016) |
"To study the protective effects of lidocaine and nerve growth factor (NGF) pretreatment on cerebral ischemia/reperfusion (I/R) injury." | 7.76 | [A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils]. ( Wang, DF; Xie, JD, 2010) |
"Data pertaining to breed; time lag to admission; clinical, clinicopathologic, and surgical findings; lidocaine treatment; and postoperative complications were assessed for association with outcome." | 7.74 | Evaluation of lidocaine treatment and risk factors for death associated with gastric dilatation and volvulus in dogs: 112 cases (1997-2005). ( Bdolah-Abram, T; Bruchim, Y; Buber, T; Epstein, A; Ranen, E; Saragusty, J, 2007) |
"Our observations indicate that lidocaine reduces reperfusion injury and inhibits PMN adhesion and subsequent migration to the lung allograft." | 7.69 | Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts. ( Ando, K; Cooper, JD; Patterson, GA; Schmid, RA; Tanaka, Y; Yamashita, M, 1996) |
"Lidocaine has anti-inflammatory properties." | 5.62 | Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery. ( Carricondo, F; Cebollero, M; García-Aldao, U; Garutti, I; Martín-Albo, L; Ortega, J; Romera, A; Romero-Gómez, B; Simón, C; Vara, E; Zapatero, S, 2021) |
"Lidocaine has proven anti-inflammatory activity in several tissues but its modulation of miRNAs has not been investigated." | 5.43 | Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury. ( Calvo, A; Casanova, J; García, C; Garutti, I; Marchal-Duval, E; Paredes, SD; Rancan, L; Rincón, D; Simón, C; Turrero, A; Vara, E, 2016) |
"Lidocaine inhibited the increase in MDA level associated with IR injury while showing no influence over increases in number of neutrophils and tissue MPO level, and it elevated the flap survival rate." | 5.37 | The impact of lidocaine on flap survival following reperfusion injury. ( Canoz, O; Eskitascioglu, T; Gunay, GK; Karaci, S; Kılıc, E, 2011) |
"The primary aim of this study was to compare the effects of a small-dose infusion of 2 antioxidant agents, ketamine and lidocaine, on ischemia-reperfusion injury (IRI) in patients undergoing elective lower limb surgery." | 5.30 | The effects of ketamine and lidocaine on free radical production after tourniquet-induced ischemia-reperfusion injury in adults. ( Deyişli, C; Kıyıcı, A; Ökesli, S; Peker, K, 2019) |
" Riluzole, Lidocaine and Lamotrigine were given prior to renal ischemia only (IO) or IRI." | 4.12 | Pharmacological prevention of renal ischemia-reperfusion injury in a rat model. ( Deng, Y; Li, RW; Smith, PN; Weiss, S; Yang, YL, 2022) |
" This study aimed to investigate whether lidocaine relieves SCIRI via modulating myocardial infarction-associated transcript (MIAT)-mediated Notch1 downregulation." | 4.12 | Lidocaine relieves spinal cord ischemia-reperfusion injury via long non-coding RNA MIAT-mediated Notch1 downregulation. ( Hou, J; Li, H; Ma, J; Xue, C, 2022) |
" The lower cell counts of caspase- and calprotectin-positive cells in group X may indicate a beneficial effect of xylazine on ischaemia/reperfusion injury." | 4.02 | Preconditioning with lidocaine and xylazine in experimental equine jejunal ischaemia. ( Kästner, S; König, K; Neudeck, S; Pfarrer, C; Rohn, K; Twele, L; Verhaar, N, 2021) |
" The aim of our research was to compare molsidomine, SIN-1, SIN-1A, and lidocaine influence on arrhythmias and hemodynamic parameters in 2 experimental models in rats." | 3.85 | New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology. ( Krzemiński, TF; Mitręga, KA; Porc, M; Żorniak, M, 2017) |
"To evaluate the effects of an intraperitoneal solution of methylene blue (MB), lidocaine and pentoxyphylline (PTX) on intestinal ischemic and reperfusion injury." | 3.83 | Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats. ( Cerri, S; Farca, AM; Gandini, M; Giusto, G; Iussich, S; Pregel, P; Tursi, M; Vercelli, C, 2016) |
"In vivo administration of lidocaine allowed maintenance of contractile performance after an ischemia and reperfusion injury." | 3.77 | Effects of in vivo lidocaine administration at the time of ischemia and reperfusion on in vitro contractility of equine jejunal smooth muscle. ( Feige, K; Geburek, F; Guschlbauer, M; Hoppe, S; Hopster, K; Huber, K; Pröpsting, MJ, 2011) |
"To study the protective effects of lidocaine and nerve growth factor (NGF) pretreatment on cerebral ischemia/reperfusion (I/R) injury." | 3.76 | [A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils]. ( Wang, DF; Xie, JD, 2010) |
" The present study was designed to examine the effects of hypoxia/reperfusion on the disposition of glutamate and propranolol in the rat isolated perfused liver." | 3.74 | Effects of hypoxia/reperfusion injury on drug disposition in the rat isolated perfused liver. ( Arab, HA; Cheung, K; Hickman, PE; Kadkhodaee, M; Potter, JM; Roberts, MS, 2007) |
"Data pertaining to breed; time lag to admission; clinical, clinicopathologic, and surgical findings; lidocaine treatment; and postoperative complications were assessed for association with outcome." | 3.74 | Evaluation of lidocaine treatment and risk factors for death associated with gastric dilatation and volvulus in dogs: 112 cases (1997-2005). ( Bdolah-Abram, T; Bruchim, Y; Buber, T; Epstein, A; Ranen, E; Saragusty, J, 2007) |
"Lidocaine and thiopental improve recovery when administrated during hypoxia and ischemia; however, the effect of pre- or postinsult treatment alone is unknown." | 3.73 | Pre- or postinsult administration of lidocaine or thiopental attenuates cell death in rat hippocampal slice cultures caused by oxygen-glucose deprivation. ( Bergold, PJ; Cao, H; Cottrell, JE; Kass, IS, 2005) |
"Oxygen radical production is thought to be fundamental to the pathogenesis of post-ischaemic reperfusion injury which is routinely managed with lidocaine." | 3.70 | Dose-dependent suppression of the neutrophil respiratory burst by lidocaine. ( Hyvönen, PM; Kowolik, MJ, 1998) |
") reduced or completely abolished the ventricular fibrillation (VF) induced by reperfusion after 5 min of regional ischemia, while lidocaine, a class I antiarrhythmic agent, showed less effect against VF as compared with FR168888." | 3.70 | Protective effect of FR168888, a new Na+/H+ exchange inhibitor, on ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats: in comparison with other cardioprotective compounds. ( Goto, T; Maeda, K; Ohara, F; Ohkubo, K; Ozaki, T; Seki, J; Sugimoto, T; Yamamoto, N, 1999) |
"Antiarrhythmic drugs, such as lidocaine, quinidine, and procainamide, have been shown to be effective against postischemic reperfusion injury in isolated rat lungs." | 3.69 | Amelioration of postischemic reperfusion injury by antiarrhythmic drugs in isolated perfused rat lung. ( Das, KC; Misra, HP, 1994) |
"Our observations indicate that lidocaine reduces reperfusion injury and inhibits PMN adhesion and subsequent migration to the lung allograft." | 3.69 | Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts. ( Ando, K; Cooper, JD; Patterson, GA; Schmid, RA; Tanaka, Y; Yamashita, M, 1996) |
"Lidocaine has anti-inflammatory properties." | 1.62 | Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery. ( Carricondo, F; Cebollero, M; García-Aldao, U; Garutti, I; Martín-Albo, L; Ortega, J; Romera, A; Romero-Gómez, B; Simón, C; Vara, E; Zapatero, S, 2021) |
"Lidocaine has a proven anti-inflammatory activity in several tissues but its modulation of glycocalyx has not been investigated." | 1.48 | Glycocalyx Degradation after Pulmonary Transplantation Surgery. ( Aymonnier, K; Casanova, J; Garutti, I; Muñoz, C; Rancan, L; Sánchez Pedrosa, G; Shahani, PM; Simón, C; Vara, E, 2018) |
"Lidocaine has proven anti-inflammatory activity in several tissues but its modulation of miRNAs has not been investigated." | 1.43 | Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury. ( Calvo, A; Casanova, J; García, C; Garutti, I; Marchal-Duval, E; Paredes, SD; Rancan, L; Rincón, D; Simón, C; Turrero, A; Vara, E, 2016) |
"Lidocaine inhibited the increase in MDA level associated with IR injury while showing no influence over increases in number of neutrophils and tissue MPO level, and it elevated the flap survival rate." | 1.37 | The impact of lidocaine on flap survival following reperfusion injury. ( Canoz, O; Eskitascioglu, T; Gunay, GK; Karaci, S; Kılıc, E, 2011) |
" The protection of mitochondrial functions was almost complete at a dosage of 10 mg/kg/day during normothermic ischemia and 10 microg/ml in the preservation liquid during hypothermic ischemia." | 1.35 | Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N'-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand. ( Ferchichi, H; Klouz, A; Kourda, N; Lakhal, M; Morin, D; Ouanes, L; Saïd, DB; Tillement, JP, 2008) |
"Lidocaine and phenol were injected into the sciatic nerves of the rats in Groups 1 and 2, respectively." | 1.32 | Free radical-induced damage in experimental peripheral nerve injection injury. ( Apan, A; Kisa, U; Saray, A, 2003) |
"Lidocaine has actions potentially of benefit during ischaemia-reperfusion." | 1.32 | The effect of lidocaine on neutrophil CD11b/CD18 and endothelial ICAM-1 expression and IL-1beta concentrations induced by hypoxia-reoxygenation. ( Harmon, D; Lan, W; Redmond, P; Shorten, G; Wang, JH, 2004) |
"Paraplegia secondary to spinal cord ischemia is a devastating complication in operations on the descending and thoracoabdominal aorta." | 1.31 | Regional lidocaine infusion reduces postischemic spinal cord injury in rabbits. ( Apaydin, AZ; Büket, S, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (17.39) | 18.2507 |
2000's | 15 (32.61) | 29.6817 |
2010's | 16 (34.78) | 24.3611 |
2020's | 7 (15.22) | 2.80 |
Authors | Studies |
---|---|
Deng, Y | 1 |
Li, RW | 1 |
Yang, YL | 1 |
Weiss, S | 1 |
Smith, PN | 1 |
Franko, JJ | 1 |
Vu, MM | 1 |
Parsons, ME | 1 |
Conner, JR | 1 |
Lammers, DT | 1 |
Ieronimakis, N | 1 |
Reynolds, GD | 1 |
Eckert, MJ | 1 |
Bingham, JR | 1 |
Hou, J | 1 |
Li, H | 1 |
Xue, C | 1 |
Ma, J | 1 |
Verhaar, N | 1 |
Pfarrer, C | 1 |
Neudeck, S | 1 |
König, K | 1 |
Rohn, K | 1 |
Twele, L | 1 |
Kästner, S | 1 |
Del Rio, M | 1 |
Lopez-Cabrera, P | 1 |
Malagón-López, P | 1 |
Del Caño-Aldonza, MC | 1 |
Castello, JR | 1 |
Provencio, M | 1 |
Romera, A | 1 |
Cebollero, M | 1 |
Romero-Gómez, B | 1 |
Carricondo, F | 1 |
Zapatero, S | 1 |
García-Aldao, U | 1 |
Martín-Albo, L | 1 |
Ortega, J | 1 |
Vara, E | 3 |
Garutti, I | 3 |
Simón, C | 3 |
Conner, J | 1 |
Lammers, D | 1 |
Holtestaul, T | 1 |
Jones, I | 1 |
Kuckelman, J | 1 |
Letson, H | 1 |
Dobson, G | 1 |
Eckert, M | 1 |
Bingham, J | 1 |
Rancan, L | 2 |
Sánchez Pedrosa, G | 1 |
Aymonnier, K | 1 |
Shahani, PM | 1 |
Casanova, J | 2 |
Muñoz, C | 1 |
Peker, K | 1 |
Ökesli, S | 1 |
Kıyıcı, A | 2 |
Deyişli, C | 1 |
Granfeldt, A | 3 |
Shi, W | 1 |
Schmarkey, SL | 1 |
Jiang, R | 1 |
Bone, CC | 1 |
Cline, JM | 1 |
Wogensen, L | 1 |
Dobson, GP | 2 |
Tønnesen, E | 2 |
Vinten-Johansen, J | 1 |
Tappenbeck, K | 2 |
Hoppe, S | 4 |
Reichert, C | 1 |
Feige, K | 4 |
Huber, K | 4 |
Nielsen, TK | 1 |
Hvas, CL | 1 |
Onoglu, R | 1 |
Narin, C | 1 |
Sarkilar, G | 1 |
Hacibeyoglu, G | 1 |
Baba, F | 1 |
Sarigul, A | 1 |
Gandini, M | 1 |
Cerri, S | 1 |
Pregel, P | 1 |
Giusto, G | 1 |
Vercelli, C | 1 |
Iussich, S | 1 |
Tursi, M | 1 |
Farca, AM | 1 |
Marchal-Duval, E | 1 |
Paredes, SD | 1 |
Calvo, A | 1 |
García, C | 1 |
Rincón, D | 1 |
Turrero, A | 1 |
Żorniak, M | 1 |
Mitręga, KA | 1 |
Porc, M | 1 |
Krzemiński, TF | 1 |
Eskitascioglu, T | 1 |
Karaci, S | 1 |
Canoz, O | 1 |
Kılıc, E | 1 |
Gunay, GK | 1 |
Guschlbauer, M | 2 |
Geburek, F | 2 |
Xie, JD | 1 |
Wang, DF | 1 |
Tasi, WC | 1 |
Petersen-Jones, SM | 1 |
Huang, PY | 1 |
Lin, CT | 1 |
Hopster, K | 2 |
Pröpsting, MJ | 1 |
Kietzmann, M | 1 |
Saray, A | 1 |
Apan, A | 1 |
Kisa, U | 1 |
Lee, HT | 1 |
Krichevsky, IE | 1 |
Xu, H | 1 |
Ota-Setlik, A | 1 |
D'Agati, VD | 1 |
Emala, CW | 1 |
Chen, MY | 1 |
Li, CH | 1 |
Huang, ZQ | 1 |
Liu, JC | 1 |
Zhou, NX | 1 |
Huang, XQ | 1 |
Wang, YS | 1 |
Lan, W | 2 |
Harmon, D | 2 |
Wang, JH | 2 |
Ghori, K | 1 |
Shorten, G | 2 |
Redmond, P | 2 |
Eghtesadi-Araghi, P | 1 |
Marashi, SM | 1 |
Cao, H | 1 |
Kass, IS | 2 |
Cottrell, JE | 2 |
Bergold, PJ | 1 |
Arab, HA | 1 |
Cheung, K | 1 |
Hickman, PE | 1 |
Potter, JM | 1 |
Kadkhodaee, M | 1 |
Roberts, MS | 1 |
Buber, T | 1 |
Saragusty, J | 1 |
Ranen, E | 1 |
Epstein, A | 1 |
Bdolah-Abram, T | 1 |
Bruchim, Y | 1 |
Klouz, A | 1 |
Saïd, DB | 1 |
Ferchichi, H | 1 |
Kourda, N | 1 |
Ouanes, L | 1 |
Lakhal, M | 1 |
Tillement, JP | 1 |
Morin, D | 1 |
Cook, VL | 1 |
Blikslager, AT | 1 |
Walsh, RM | 1 |
Tanaka, J | 1 |
Malchesky, PS | 1 |
Sato, N | 1 |
Nakayama, S | 1 |
Vogt, DP | 1 |
Broughan, TA | 1 |
Hermann, RE | 1 |
Castellani, WJ | 1 |
Das, KC | 1 |
Misra, HP | 1 |
Kim-Lee, MH | 1 |
Stokes, BT | 1 |
McDonald, JS | 1 |
Schmid, RA | 1 |
Yamashita, M | 1 |
Ando, K | 1 |
Tanaka, Y | 1 |
Cooper, JD | 1 |
Patterson, GA | 1 |
Leclercq, I | 1 |
Saliez, A | 1 |
Wallemacq, PE | 1 |
Horsmans, Y | 1 |
Lambotte, L | 1 |
Hyvönen, PM | 1 |
Kowolik, MJ | 1 |
Tomori, H | 1 |
Shiraishi, M | 1 |
Koga, H | 1 |
Toure, M | 1 |
Taira, K | 1 |
Higa, T | 1 |
Okuhama, Y | 1 |
Hiroyasu, S | 1 |
Muto, Y | 1 |
Ohara, F | 1 |
Sugimoto, T | 1 |
Yamamoto, N | 1 |
Ohkubo, K | 1 |
Ozaki, T | 1 |
Maeda, K | 1 |
Seki, J | 1 |
Goto, T | 1 |
Izuishi, K | 1 |
Wakabayashi, H | 1 |
Maeba, T | 1 |
Ryu, M | 1 |
Maeta, H | 1 |
Marx, G | 1 |
Leuwer, M | 1 |
Höltje, M | 1 |
Bornscheuer, A | 1 |
Herrmann, H | 1 |
Mahr, KH | 1 |
Vangerow, B | 1 |
Heine, J | 1 |
Piepenbrock, S | 1 |
Rueckoldt, H | 1 |
Lei, B | 1 |
Apaydin, AZ | 1 |
Büket, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
2 reviews available for lidocaine and Reperfusion Injury
Article | Year |
---|---|
Organ dysfunction following regional and global ischemia/reperfusion. Intervention with postconditioning and adenocaine.
Topics: Adenosine; Animals; Anti-Arrhythmia Agents; Drug Combinations; Heart Arrest; Humans; Ischemia; Ische | 2012 |
Use of systemically administered lidocaine in horses with gastrointestinal tract disease.
Topics: Animals; Anti-Inflammatory Agents; Gastrointestinal Diseases; Horse Diseases; Horses; Ileus; Lidocai | 2008 |
3 trials available for lidocaine and Reperfusion Injury
Article | Year |
---|---|
Effect of intravenous lidocaine on ischemia-reperfusion injury in DIEP microsurgical breast reconstruction. A prospective double-blind randomized controlled clinical trial.
Topics: Adult; Anesthetics, Local; Biomarkers; Breast Neoplasms; Double-Blind Method; Epigastric Arteries; F | 2021 |
The effects of ketamine and lidocaine on free radical production after tourniquet-induced ischemia-reperfusion injury in adults.
Topics: Adult; Biomarkers; Free Radicals; Humans; Ketamine; Lactates; Lidocaine; Lower Extremity; Reperfusio | 2019 |
Low-dose dopexamine in patients undergoing hemihepatectomy: an evaluation of effects on reduction of hepatic dysfunction and ischaemic liver injury.
Topics: Adult; Aged; Antithrombin III; Dopamine; Dopamine Agonists; Double-Blind Method; Female; Hemodynamic | 2000 |
41 other studies available for lidocaine and Reperfusion Injury
Article | Year |
---|---|
Pharmacological prevention of renal ischemia-reperfusion injury in a rat model.
Topics: Animals; Glutathione; Humans; Ischemia; Kidney; Lamotrigine; Lidocaine; Rats; Reperfusion Injury; Ri | 2022 |
Adenosine, lidocaine, and magnesium for attenuating ischemia reperfusion injury from resuscitative endovascular balloon occlusion of the aorta in a porcine model.
Topics: Adenosine; Animals; Aorta; Balloon Occlusion; Disease Models, Animal; Endovascular Procedures; Hemor | 2022 |
Lidocaine relieves spinal cord ischemia-reperfusion injury via long non-coding RNA MIAT-mediated Notch1 downregulation.
Topics: Animals; Down-Regulation; Lidocaine; Mice; Myocardial Infarction; Reperfusion Injury; RNA, Long Nonc | 2022 |
Preconditioning with lidocaine and xylazine in experimental equine jejunal ischaemia.
Topics: Animals; Horse Diseases; Horses; Ischemia; Lidocaine; Reperfusion Injury; Xylazine | 2021 |
Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosi | 2021 |
Combatting ischemia reperfusion injury from resuscitative endovascular balloon occlusion of the aorta using adenosine, lidocaine and magnesium: A pilot study.
Topics: Adenosine; Animals; Anti-Inflammatory Agents; Aorta; Balloon Occlusion; Disease Models, Animal; Drug | 2021 |
Glycocalyx Degradation after Pulmonary Transplantation Surgery.
Topics: Animals; Cell Adhesion; Glycocalyx; Heparitin Sulfate; Lidocaine; Lung Transplantation; Male; Neutro | 2018 |
The effects of adenocaine (adenosine and lidocaine) on early post-resuscitation cardiac and neurological dysfunction in a porcine model of cardiac arrest.
Topics: Adenosine; Animals; Brain Death; Cardiopulmonary Resuscitation; Cardiovascular Agents; Coronary Angi | 2013 |
In vitro effects of lidocaine on contractility of circular and longitudinal equine intestinal smooth muscle.
Topics: Anesthetics, Local; Animals; Female; Horse Diseases; Horses; In Vitro Techniques; Isometric Contract | 2013 |
Pulmonary function after hemorrhagic shock and resuscitation in a porcine model.
Topics: Acute Lung Injury; Adenosine; Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Cytokines; Drug Comb | 2014 |
The Potential Effect of Epidural Anesthesia on Mesenteric Injury after Supraceliac Aortic Clamping in a Rabbit Model.
Topics: Anesthesia, Epidural; Anesthetics, Local; Animals; Aorta, Abdominal; Biomarkers; Constriction; Disea | 2016 |
Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats.
Topics: Animals; Anti-Inflammatory Agents; Drug Combinations; Drug Synergism; Inflammation; Infusions, Paren | 2016 |
Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury.
Topics: Animals; Apoptosis Regulatory Proteins; Disease Models, Animal; Gene Expression Regulation; Inflamma | 2016 |
New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
Topics: Animals; Anti-Asthmatic Agents; Arrhythmias, Cardiac; Creatine Kinase; Disease Models, Animal; Hemod | 2017 |
The impact of lidocaine on flap survival following reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Lidocaine; Malondialdehyde; Mod | 2011 |
In vitro effects of lidocaine on the contractility of equine jejunal smooth muscle challenged by ischaemia-reperfusion injury.
Topics: Animals; Creatine Kinase; Female; Horses; Jejunum; Lidocaine; Male; Muscle Contraction; Muscle, Smoo | 2010 |
[A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils].
Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Gerbillinae; Ischemic Preconditioning; L | 2010 |
The neuroprotective effects of lidocaine and methylprednisolone in a rat model of retinal ischemia-reperfusion injury.
Topics: Anesthetics, Local; Animals; Anti-Inflammatory Agents; Blindness; Electroretinography; Intraocular P | 2012 |
Effects of in vivo lidocaine administration at the time of ischemia and reperfusion on in vitro contractility of equine jejunal smooth muscle.
Topics: Anesthetics, Local; Animals; Chromatography, High Pressure Liquid; Colic; Creatine Kinase; Female; H | 2011 |
Lidocaine and structure-related mexiletine induce similar contractility-enhancing effects in ischaemia-reperfusion injured equine intestinal smooth muscle in vitro.
Topics: Animals; Creatine Kinase; Horses; Intestines; Lidocaine; Male; Mexiletine; Muscle Contraction; Muscl | 2013 |
Free radical-induced damage in experimental peripheral nerve injection injury.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Disease Models, Animal; Immunohistochemistry; Injury | 2003 |
Local anesthetics worsen renal function after ischemia-reperfusion injury in rats.
Topics: Anesthetics, Local; Animals; Apoptosis; Blood Pressure; Bupivacaine; Gene Expression; Heart Rate; In | 2004 |
Protective effects of lidocaine injected into the hepatoduodenal ligament on warm ischemia-reperfusion injury to the rat liver.
Topics: Animals; Duodenum; Injections; Lidocaine; Ligaments; Liver; Liver Diseases; Male; Rats; Rats, Spragu | 2004 |
The effect of lidocaine on in vitro neutrophil and endothelial adhesion molecule expression induced by plasma obtained during tourniquet-induced ischaemia and reperfusion.
Topics: Adolescent; Adult; Analysis of Variance; Anesthetics, Local; Cell Adhesion Molecules; Endothelial Ce | 2004 |
The effect of lidocaine on neutrophil CD11b/CD18 and endothelial ICAM-1 expression and IL-1beta concentrations induced by hypoxia-reoxygenation.
Topics: Analysis of Variance; Anesthetics, Local; CD11b Antigen; CD18 Antigens; Cell Hypoxia; Cells, Culture | 2004 |
Comparison of propofol with lidocaine pretreatment versus propofol formulated with long- and medium-chain triglycerides or confounding effect of tourniquet.
Topics: Anesthetics, Intravenous; Anesthetics, Local; Chemistry, Pharmaceutical; Excipients; Humans; Injecti | 2005 |
Pre- or postinsult administration of lidocaine or thiopental attenuates cell death in rat hippocampal slice cultures caused by oxygen-glucose deprivation.
Topics: Animals; Cell Death; Cell Hypoxia; Glucose; Hippocampus; Ischemia; Lidocaine; Neuroprotective Agents | 2005 |
Effects of hypoxia/reperfusion injury on drug disposition in the rat isolated perfused liver.
Topics: Adrenergic beta-Antagonists; Animals; Aspartate Aminotransferases; Carbon Dioxide; Carbon Radioisoto | 2007 |
Evaluation of lidocaine treatment and risk factors for death associated with gastric dilatation and volvulus in dogs: 112 cases (1997-2005).
Topics: Animals; Breeding; Dog Diseases; Dogs; Female; Gastric Dilatation; Genetic Predisposition to Disease | 2007 |
Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N'-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand.
Topics: Adenosine Triphosphate; Animals; Biotransformation; Cell Membrane; Cell Respiration; Cold Ischemia; | 2008 |
Monoethylglycinexylidide formation as an independent measure of warm hepatic ischemia and reperfusion injury.
Topics: Adenosine Triphosphate; Animals; Hot Temperature; Lidocaine; Liver; Liver Diseases; Male; Mitochondr | 1995 |
Amelioration of postischemic reperfusion injury by antiarrhythmic drugs in isolated perfused rat lung.
Topics: Animals; Anti-Arrhythmia Agents; In Vitro Techniques; Ischemia; Lidocaine; Lung; Male; Organ Size; P | 1994 |
Procaine, lidocaine, and hypothermia inhibit calcium paradox in glial cells.
Topics: Analysis of Variance; Calcium; Carrier Proteins; Humans; Hypothermia; Lidocaine; Neuroglia; Procaine | 1994 |
Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts.
Topics: Animals; CD11 Antigens; Cell Adhesion; Chemotaxis, Leukocyte; Disease Models, Animal; Dogs; Flow Cyt | 1996 |
The monoethylglycinexylidide test does not correctly evaluate lidocaine metabolism after ischemic liver injury in the rat.
Topics: Animals; Bilirubin; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Enzymes; F | 1997 |
Dose-dependent suppression of the neutrophil respiratory burst by lidocaine.
Topics: Adult; Analgesics; Anesthetics, Local; Anti-Inflammatory Agents; Area Under Curve; Biocompatible Mat | 1998 |
Protective effects of lidocaine in hepatic ischemia/reperfusion injury in vitro.
Topics: Animals; Aspartate Aminotransferases; In Vitro Techniques; Ischemia; Lidocaine; Liver; Liver Circula | 1998 |
Protective effect of FR168888, a new Na+/H+ exchange inhibitor, on ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats: in comparison with other cardioprotective compounds.
Topics: Anesthesia; Animals; Arrhythmias, Cardiac; Benzyl Alcohol; Benzyl Alcohols; Diltiazem; Dose-Response | 1999 |
Lidocaine-metabolizing activity after warm ischemia and reperfusion of the rat liver in vivo.
Topics: Alanine Transaminase; Anesthetics, Local; Animals; Cytochrome P-450 Enzyme System; Lidocaine; Liver; | 2000 |
Neuroprotective effect of low-dose lidocaine in a rat model of transient focal cerebral ischemia.
Topics: Anesthetics, Local; Animals; Blood Gas Analysis; Body Weight; Brain Infarction; Brain Ischemia; Hemo | 2001 |
Regional lidocaine infusion reduces postischemic spinal cord injury in rabbits.
Topics: Anesthesia, Conduction; Anesthetics, Local; Animals; Infusions, Intra-Arterial; Lidocaine; Paraplegi | 2001 |